Doree F Sitkoff

This inventor holds 14 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company. Active years: 2008-2024.

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 7.8

ph-index = 6

Forward Citations = 141(Granted Patents)

Company Filing History:

13 out of 3,736

Bristol-Myers Squibb Compnay

patents

1 out of 41

Bristol Meyers Squibb Company

patents

Years Active: 2008-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858979 - Fibronectin based scaffold domain proteins that bind PCSK9 (2024-01-02),

2. 10947297 - Fibronectin based scaffold domain proteins that bind PCSK9 (2021-03-16),

3. 10123993 - Cyclic ureas as inhibitors of rock (2018-11-13),

4. 10112939 - Tied-back benzamide derivatives as potent rock inhibitors (2018-10-30),

5. 10112929 - Lactams as inhibitors of rock (2018-10-30),

6. 9856309 - Fibronectin based scaffold domain proteins that bind PCSK9 (2018-01-02),

7. 9234027 - Fibronectin based scaffold domain proteins that bind PCSK9 (2016-01-12),

8. 8420098 - Fibronectin based scaffold domain proteins that bind to PCSK9 (2013-04-16),

9. 8119808 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators (2012-02-21),

10. 7884113 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators (2011-02-08),

11. 7858639 - Bicyclic heterocycles as cannabinoid-1 receptor modulators (2010-12-28),

12. 7632837 - Bicyclic heterocycles as cannabinoid-1 receptor modulators (2009-12-15),

13. 7378418 - Azabicyclic heterocycles as cannabinoid receptor modulators (2008-05-27),

14. 7317012 - Bicyclic heterocycles as cannabinoind-1 receptor modulators (2008-01-08),

Title: The Innovative Journey of Doree F Sitkoff

Introduction

Doree F Sitkoff, based in Dresher, PA, has made significant contributions to the field of biotechnology through his innovative inventions. With a robust portfolio of 14 patents, Sitkoff stands out for his research focused on therapeutic applications aimed at treating cholesterol-related diseases.

Latest Patents

Sitkoff's latest patents involve fibronectin-based scaffold domain proteins that exhibit the ability to bind PCSK9. This groundbreaking invention not only addresses the binding mechanism but also emphasizes the therapeutic potential of these innovative proteins in the treatment of atherosclerosis, hypercholesterolemia, and various cholesterol-related ailments. Additionally, these patents cover the utility of cells comprising such proteins, polynucleotides encoding these proteins or their fragments, as well as vectors that include the polynucleotides encoding the innovative protein.

Career Highlights

Doree F Sitkoff has worked with renowned companies, including Bristol Myers Squibb Company, where he has honed his expertise in biopharmaceuticals. His contributions have led to advancements that bridge the gap between fundamental research and practical medical applications.

Collaborations

Throughout his career, Sitkoff has collaborated with esteemed colleagues, including Chongqing Sun and Yanting Huang. These collaborations have likely enriched his research and enhanced the impact of his inventions in the scientific community.

Conclusion

Doree F Sitkoff's inventive spirit and dedication to developing therapeutic solutions underscore his importance in the biotechnology sector. As his work continues to evolve, the implications of his innovations may lead to significant advancements in treatments for cholesterol-related diseases, benefiting countless individuals worldwide.